Apellis Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 8, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-08

Reporting Person: Deschatelets Pascal (Chief Operating Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	561452	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$2.14	2020-05-12	Common Stock (234411)		Direct
Stock Option (right to buy)	$2.67	2023-12-04	Common Stock (398499)		Direct
Stock Option (right to buy)	$3.67	2026-02-07	Common Stock (227494)		Direct
Stock Option (right to buy)	$4.31	2027-08-22	Common Stock (187529)		Direct

Footnotes

F1: This option was granted on May 12, 2010 and is fully vested.

F2: This option was granted on December 5, 2013 and has vested as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

F3: This option was granted on February 8, 2016 and has vested as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

F4: This option was granted on August 21, 2017 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.